SPAC Feed’s Post

I love watching these retail investor trades play out - traders hustling all the time to make money in this market! Medical Technology Stocks in Play - SOBR Safe, Inc. (NASDAQ: SOBR) Gets Investors High on Stock Run #stockstowatch #trading #stockmarketnews #investing #investors #medicaltech #breathalyzers

In the Canadian healthcare landscape, the dental industry boasts a private payer system and low consolidation rates. What does that mean to investors? It is uniquely positioned for sustained growth and stability. You can learn about the Newlook Capital Dental Fund at https://lnkd.in/gh5vSxY3. If you have any questions, or for more information, we invite you to reach out to our team. #DentalIndustry #Investing #Investors #PrivateEquity #CanadianHealthcare #InvestmentOpportunity

With an established US provider base, CoachCare advanced to the middle market through smart growth and acquisitions. Who would know if not for a carefully crafted narrative highlighting the remote patient monitoring company's strategy for expansion and financial acumen. Our earned media campaigns always include the voice of the customers. By building credibility before liquidity events, we secured coverage in top financial and healthcare outlets. The strategy resulted in an impressive double-digit ROI, boosting awareness among customers, strategic partners, investment bankers, buyers and private equity firms. Read the full case study here. Fortune's Term Sheet Healthcare IT News, Mergers and Acquisitions - themiddlemarket.com Mergermarket, Crain's New York Business The Deal #digitalhealth #investment #strategicgrowth #privateequity #mergersandacquisitions #healthcareinnovation #startupsuccess #venturecapital #financialPR #investorrelations

We value hundreds of businesses each year for purposes of assisting with minority interest acquisitions, joint ventures, and control acquisitions, among others. HealthCare Appraisers provides business valuation services in connection with a wide variety of healthcare transactions. Learn more about how we can help you streamline your business valuation needs. https://lnkd.in/gQrUtsMk #healthcarevaluation #businessvaluationexperts #businessvaluation #fairmarketvalue

💰 Over the past decade, private equity funds investing in companies such as dental support organizations (DSOs) could rely on cheap credit, high amounts of leverage, and multiple expansion (a form of valuation arbitrage) to maximize their returns. 📊 The next decade will require private equity funds to focus on getting better in two specific areas: 1️⃣ M&A deal sourcing. 2️⃣ Making operational improvements to their portfolio companies; for DSOs, this includes more effective revenue cycle management (RCM). #SinaAmiri #healthcare #privateequity #investing

Nordic Capital’s recent pivot to sell Sunrise Medical to Platinum Equity, just after disclosing IPO plans, underscores the importance of transaction readiness in the current environment. The Wall Street Journal article linked below by Maria Armental also highlights Battery Ventures’ sale of AuditBoard to Hg following a similar pivot away from an IPO. Having a dual-track exit strategy provides the flexibility to seize the most compelling course. Amid current market uncertainties, flexibility is key. While an IPO or capital raise may maximize potential returns, an outright sale allows for a full exit and return of capital to cash-starved LPs. #Ankura Office of the CFO  #PrivateEquity  #TransactionReadiness  #MergersAndAcquisitions

📣 TPG & Blackstone Team Up to Bid for Bausch + Lomb in Deal Valued up to $14 Billion Private equity heavyweights TPG and Blackstone have joined forces to place a bid for eye care giant Bausch + Lomb. The deal, which could value the company between $13 billion and $14 billion, represents a significant move in the healthcare space. This joint effort comes as part of a sale process led by Goldman Sachs to resolve tensions over Bausch Health Companies Inc. Health's substantial debt. 🔎 Why This Deal Matters: Strategic Partnership: Both TPG and Blackstone have strong ties to the healthcare sector, with TPG already owning ophthalmology firm BVI Medical. Their bid signals confidence in the long-term potential of Bausch + Lomb's core businesses, such as contact lenses and eye care drugs. Debt-Driven Sale: The sale is a strategic response to disputes arising from Bausch Health’s $21 billion debt load. Bausch Health, which still holds an 88% stake in Bausch + Lomb, needs to address upcoming debt maturities, including a $2.4 billion loan due next year. Growth Potential: Bausch + Lomb is expected to generate nearly $860 million in adjusted EBITDA on $4.7 billion in revenue this year, making it an attractive target for private equity players. With 60% of revenue coming from contact lenses and eye care drugs, there’s a solid foundation for future growth. 📈 Market Reaction: Since reports of the sale, shares of Bausch + Lomb have surged by 25%, closing at $19.47. The company’s valuation in the deal could reach up to $25 per share, signaling a strong premium for investors. 👁 What’s Next: Formal bids are expected by the end of the month, but the process is still evolving. Major lenders and shareholders, including Carl Icahn and John Paulson, are closely watching how proceeds from a potential sale might be allocated to address Bausch Health’s debt and future obligations. This deal is one to watch, as it could reshape the landscape of the eye care industry while helping Bausch Health tackle its debt challenges. Stay tuned for updates as we track the progress of this high-profile transaction! #PrivateEquity #MergersAndAcquisitions #Healthcare #BauschLomb #TPG #Blackstone #EquityGen #DebtRestructuring #Investment

📋✨ Every company needs an exit strategy, but in our experience, many don't have one. Just like selling your home, prepping for the market takes work. Make sure you are prepared when the time comes to consider a sale of your business. 📅🗂️ Download our acquisition preparation checklist to get started! #ABAClinic #ExitStrategy #BusinessPrep #M&A #SuccessPlan

SPACs are increasingly used to take private healthcare companies public, offering an alternative to traditional IPOs. This trend has been growing, especially between 2012 and 2021. SPACs provide a pathway to public markets for companies that may not meet traditional IPO financial performance targets. They also typically incur lower underwriting fees and are less likely to face shareholder lawsuits. 👉 SPACs could lead to higher prices for healthcare services and products due to increased consolidation and vertical integration .... ultimately raising costs for employers, insurers, and patients. 👉 Corporatization of healthcare through SPACs may result in adverse clinical events, as seen with previous private equity acquisitions. 👉 The need for regulatory compliance and transparency may present challenges. 👉 SPACs can be risky investments, as they often merge with companies that have not yet achieved profitability. 💡 Financial engineering and creating value in the healthcare value chain are two distinct pursuits. #SPACs #SVP #HealthcareIPO #Digitalhealth

NEW: Bausch + Lomb, one of the world’s largest contact lens suppliers, is exploring a sale as a way out of a messy separation from its heavily indebted parent company that has been opposed by lenders including Apollo Global Management. The eye care business — which was carved out of Bausch Health, formerly known as Valeant, in 2020 — is working with advisers from Goldman Sachs to test interest from potential buyers. Bausch + Lomb is likely to draw interest from private equity groups. Bausch + Lomb’s enterprise value including debt stood at just over $10bn, based on its share price at market close on Friday. Any deal to sell the business was likely to come at a sizeable premium to the current valuation as Bausch + Lomb’s business has been performing well. Bausch + Lomb’s chief executive Brent Saunders is a well-known dealmaker who oversaw Allergan’s $63bn sale to AbbVie.